Acumen Pharmaceuticals, Inc. Stock Price, News & Analysis

Acumen Pharmaceuticals (NASDAQ: ABOS) announced that its investigational drug, ACU193, has received Fast Track designation from the FDA for treating early Alzheimer’s disease. ACU193 targets toxic soluble amyloid beta oligomers, which are believed to contribute to neurodegeneration. Currently in the Phase 1 INTERCEPT-AD trial, the drug aims to establish safety and proof of mechanism with 62 participants. The Fast Track status facilitates closer collaboration with the FDA, enhancing the potential for expedited review and approval.

Acumen Pharmaceuticals (NASDAQ: ABOS) reported financial results for Q2 2022, revealing a cash balance of $209.9 million as of June 30, anticipated to fund operations until 2025. The ongoing INTERCEPT-AD Phase 1 trial for ACU193 aims to deliver topline results in H1 2023, with 15 active clinical sites currently enrolling patients. R&D expenses surged to $7.3 million, reflecting increased clinical trial costs. Net loss decreased to $10.2 million compared to $61.4 million a year prior, influenced by significant prior year non-cash expenses.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will announce its Q2 2022 financial results on August 15, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on novel therapies for Alzheimer’s disease and is advancing its investigational drug, ACU193, in a Phase I clinical trial. Acumen has established itself in the biopharmaceutical sector, targeting the toxic Aβ oligomers linked to Alzheimer’s pathology. The audio from the call will be accessible via their website, with an archived version available for 30 days.

Acumen Pharmaceuticals has developed a synthetic model for soluble amyloid beta oligomers (AβOs), crucial for Alzheimer’s disease research. This model aims to standardize assays for AβOs, which have been challenging to study due to their complexity. The methodology will be presented at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. The ongoing Phase 1 clinical trial of ACU193, targeting toxic AβOs, is expected to yield important data to advance Alzheimer’s research.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.

Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2022 financial results, highlighting a cash balance of $216.7 million as of March 31, 2022, sufficient to fund operations through 2025. The company is advancing its Phase 1 clinical trial, INTERCEPT-AD, for its drug ACU193 targeting early Alzheimer’s disease, with topline data expected in the first half of 2023. R&D expenses increased to $6.0 million from $2.6 million YoY, reflecting ongoing trial costs. Acumen's net loss for the quarter was $9.1 million, a decrease from $27.0 million in Q1 2021.

Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q1 2022 financial results on May 16, 2022, at 4:30 PM ET. The company will host a conference call and a live audio webcast to discuss business performance and financial updates. Acumen is focused on developing a novel therapy for Alzheimer’s disease, specifically targeting toxic AβOs through its investigational drug, ACU193, currently in Phase I trials. Interested investors can access the live webcast via the company’s website.

Acumen Pharmaceuticals (NASDAQ: ABOS) announces publication in Frontiers in Neuroscience of preclinical evidence supporting ACU193, a monoclonal antibody targeting amyloid beta oligomers for early Alzheimer's disease treatment. The publication indicates that AβO-mediated neuronal toxicity contributes to cognitive impairments in Alzheimer's patients. Key findings include ACU193's selectivity towards AβOs without binding to plaques, suggesting a reduced risk of amyloid-related imaging abnormalities. Ongoing Phase I clinical trials aim to validate these findings and explore ACU193's therapeutic potential.

Acumen Pharmaceuticals (NASDAQ: ABOS) reported progress on ACU193, its monoclonal antibody targeting toxic amyloid-beta oligomers, currently in Phase 1 clinical trial INTERCEPT-AD for early Alzheimer's patients. The trial has experienced slower enrollment due to COVID-19, but topline results are expected in H1 2023. Acumen ended 2021 with $225.9 million in cash, sufficient to fund operations through 2025. The company's leadership was strengthened with new appointments, including Kim Drapkin to the Board. Net losses were $100.6 million in 2021, primarily due to non-cash expenses related to fair value changes.